Anti-cancer drug paclitaxel formulations first market in the world hunger – pacl
According to latest statistics from the United States in 2006, including the processing of natural raw materials and semi-synthetic paclitaxel injection of paclitaxel injection formulation of paclitaxel, including the international market sales reached 3.7 billion U.S. dollars, ranking the world's anti-cancer drugs first.
Soon as he was listed in 1992, Taxol to be warmly welcomed by the medical profession, then that set off more than 200 million U.S. dollars in the remarkable performance, the listed sales of 7-year global market, has exceeded one billion U.S. dollars. Thus, anti-cancer drug paclitaxel to create a single preparation of plant sale miracle, even the earlier listing of plants such as vinblastine and vincristine anti-cancer drugs, sales of just over 200 million U.S. dollars so far.
Long-term supply of the market as Bristol-Myers Squibb monopoly
So far, only two kinds of the international market paclitaxel API: A variety of yew bark from; the other is the view from the European yew twigs to extract the "10 – Berry gibberellic base", and then made by semi-synthetic, or docetaxel (docetaxel), its structure is very similar to the natural extract taxol. Both APIs are international best-selling pharmaceutical bulk drugs market products, and long-term shortage in the state, according to authorities estimated that paclitaxel and docetaxel API API sales ratio of about 10:1.
In the United States, the paclitaxel injection (brand name: Paclitaxel) mainly by the Bristol-Myers Squibb an exclusive production, now around 23 pharmaceutical companies manufacturing bulk drugs and formulations of paclitaxel, but the market is basically for the Bristol-Myers Squibb by monopoly, and several other formulations of taxol production and sales together, only Bristol-Myers a fraction. The docetaxel drug substances and drug companies are mainly from France and the United Kingdom Planck, Italy co-production of several companies to the largest production Planck.
Will increase sales and booming demand for new uses
Paclitaxel in hospitals around the world are the preferred anticancer drugs. In recent years, the incidence of cancer around the world has increased more than 10 years ago nearly doubled, lung cancer, malignant tumors such as breast and ovarian cancer also showed multiple trends, these cancer patients are the main users of paclitaxel. Overall, in the absence of a plant cancer drug to take its place before the Taxol sales will rise, not fall.
According to the latest figures released by the World Health Organization, the United States has become a country of high incidence of cancer in the world, its new cancer cases each year 140 million people, about the year 14% of cancer patients worldwide. The United States has remained the largest consumer of paclitaxel. As the U.S. increased incidence of cancer, paclitaxel against advanced cancer as a major drug, it is believed the rapid increase in sales will continue to maintain the momentum. United States and other developed countries in the 10 years of clinical use of the process has already summed up a set of Taxol and other anticancer drugs, the best compatibility of all programs, the health sector can not do without paclitaxel has this "backbone", and therefore the demand for raw material drug paclitaxel also showed corresponding rise trend.
Addition for the treatment of cancer, paclitaxel in other indications have also been studies. According to Chinese media reports the United States, paclitaxel has been expanded by the use of FDA approved for the treatment of rheumatoid arthritis, is now listed on the United States have developed a topical formulation of paclitaxel treatment of rheumatoid arthritis?? Paclitaxel gel. United States, the large number of patients suffering from rheumatoid arthritis, so paclitaxel as a topical anti-inflammatory agent a promising future market. And recently, the United States Ivax biopharmaceutical company developing and producing a kind of new formulations of paclitaxel, namely higher bioavailability of "nano-paclitaxel injection." Said to have a U.S. company to produce oral formulations of paclitaxel, its composition is made to reconcile paclitaxel plus vitamin E, in addition to adding a number of polymer pharmaceutical excipients, to prevent paclitaxel was digested in the digestive tract damage. The new use of paclitaxel will greatly facilitate the drug paclitaxel raw material market.
Recent years, taxol in the use of medical equipment are also favored. U.S. medical device companies to develop a plug for the treatment of patients with severe coronary paclitaxel-eluting stent type of drug.
The new drug-eluting stent to prevent blood lipid re-deposited on the stent surface material to form a new block, which can greatly improve the life of vascular stents. Because of this drug-eluting stent intervention has become an international best-selling medical device products on the market, it was predicted that paclitaxel API was introduced in the medical device industry, will greatly increase the international pharmaceutical industry paclitaxel API's white-hot battle degree.
The e-commerce company in China offers quality products such as Nose Rinsing Device , Disposable Vaginal Speculum, and more. For more , please visit disposable medical suppliers today!
Processing your request, Please wait....
